KP Tissue Inc. (KPT) (TSX: KPT) reports the Q3 2021 financial and operational results of KPT and Kruger Products L.P. (KPLP). Kruger Products is Canada's leading manufacturer of quality tissue products for the Consumer market (Cashmere, Purex, SpongeTowels, Scotties, and White Swan) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 14.5% interest in KPLP.

KPLP Q3 2021 Business and Financial Highlights

  • Revenue increased by $22.3 million or 6.0% to $391.4 million in Q3 2021 compared to $369.1 million in Q3 2020.
  • Adjusted EBITDA was $40.3 million in Q3 2021 compared to $46.2 million in Q3 2020, a decrease of 12.8%, and improved sequentially from $37.3 million in Q2 2021.
  • TAD Sherbrooke continues to run above the expected start-up curve.
  • Declared a quarterly dividend of $0.18 per share to be paid on January 17, 2022

“Our solid revenue growth of 6% for the third quarter reflects pricing actions in our Canadian Consumer segment, combined with slightly higher volume and gradually improving commercial end-markets, along with the execution of our recovery plan in the Away-From-Home business. High inflationary costs and near-record pulp prices negatively impacted our Adjusted EBITDA compared to the same quarter last year, but the benefits of recent price increases resulted in a sequential improvement to $40.3 million for the quarter," stated KP Tissue’s Chief Executive Officer, Dino Bianco.

“Market share data in Canada for the most recent 52-week period further highlights the significant progress we have made since the beginning of 2020. In our market-leading categories we have grown bathroom tissue by 2.4 share points to 35.6% and facial tissue increased by 4.0 share points to 35.5%. In the paper towel category, we consolidated our strong second place through innovations and the introduction of new products, translating into gains of 2.6 share points to 23.2% with continued strong investments ahead.

“The Away-From-Home segment, which was hardest hit by the COVID-19 pandemic, showed further signs of recovery in the quarter with 20% year-over-year revenue growth supported in part by the faster re-opening of the U.S. economy. On the strength of higher sales volumes, more in-house paper production and cost-reduction initiatives, Adjusted EBITDA for this business turned positive in Q3 2021.

“Inflationary pressure and labour shortages are among the key challenges we will be facing in upcoming quarters. We are executing pricing actions across the business along with a more focused labour approach to manage our margins, while continuing to invest to grow the top-line in both Consumer and AFH. TAD Sherbrooke performance continues to be well ahead of our growth curve and a key enabler for future growth,” concluded Mr. Bianco.

OutlookWe are seeing activities and behaviour start to return to more pre-COVID levels in both the Consumer and Away-From-Home segments. However, cost inflation and lagged pricing in the fourth quarter are expected to impact results. Q4 2021 Adjusted EBITDA is therefore expected to be lower than Q3 2021 and higher than Q4 2020.

KPLP Q3 2021 Financial ResultsRevenue was $391.4 million in Q3 2021 compared to $369.1 million in Q3 2020, an increase of $22.3 million or 6.0%. The increase in revenue was due to a selling price increase in Consumer Canada, slightly higher sales volume in the Consumer segment compared to the year ago quarter, and an increase in sales volume in the AFH segment resulting from the beginning of COVID-19 related demand recovery. Revenue was unfavourably impacted by foreign exchange fluctuations on U.S. dollar sales.

Cost of sales was $345.6 million in Q3 2021 compared to $307.7 million in Q3 2020, an increase of $37.9 million or 12.3%. Manufacturing costs increased primarily due to higher sales volumes net of overhead absorption, increased pulp costs, labour shortages in Memphis manufacturing, higher depreciation expense and inflation. These increases were partially offset by the favourable impact of more in-house paper production in AFH and favourable foreign exchange fluctuations on U.S. dollar costs. Freight costs and warehousing expenses also increased compared to Q3 2020. As a percentage of revenue, cost of sales was 88.3% in Q3 2021 compared to 83.4% in Q3 2020.

Selling, general and administrative (SG&A) expenses were $29.0 million in Q3 2021 compared to $31.2 million in Q3 2020, a decrease of $2.2 million or 7.1%. The decrease was primarily due to a reduction in compensation related costs, the release of a COVID-19 related AFH accounts receivable provision recorded during 2020 and foreign exchange gains, partially offset by higher marketing expenses. As a percentage of revenue, SG&A expenses were 7.4% in Q3 2021 compared to 8.5% in Q3 2020.

Adjusted EBITDA was $40.3 million in Q3 2021 compared to $46.2 million in Q3 2020, a decrease of $5.9 million or 12.8%. The decrease was primarily due to the unfavourable impact of sales mix, higher pulp prices, inflation and higher freight rates and warehousing costs, partially offset by the net favourable impact of foreign exchange fluctuations and lower SG&A expenses.

Net loss was $9.3 million in Q3 2021 compared to net income of $18.5 million in Q3 2020, a decrease of $27.8 million. The decrease was primarily due to lower Adjusted EBITDA of $5.9 million, and higher other, interest and depreciation expenses, partially offset by a higher income tax recovery.

KPLP Q3 2021 Financing ActivityTotal liquidity, representing cash and availability under the revolving credit agreements, was $273.6 million as of September 30, 2021. In addition, $25.5 million of cash was held for the TAD Sherbrooke Project and $24.8 million of cash was held for the Sherbrooke Expansion Project.

KPT Q3 2021 Financial ResultsKPT had a net loss of $2.2 million in Q3 2021. Included in net loss was $1.4 million representing KPT’s share of KPLP’s net loss, depreciation expense of $1.3 million related to adjustments to carrying amounts on acquisition and an income tax recovery of $0.4 million.

Dividends on Common SharesThe Board of Directors of KPT declared a quarterly dividend of $0.18 per share to be paid on January 17, 2022 to shareholders of record at the close of business on December 31, 2021.

Additional InformationFor additional information please refer to Management’s Discussion and Analysis (MD&A) of KPT and KPLP for the third quarter ended September 30, 2021 available on SEDAR at www.sedar.com or our website at www.kptissueinc.com.

Third Quarter Results Conference Call InformationKPT will hold its third quarter conference call on Friday, November 12, 2021 at 8:30 a.m. Eastern Time.

Via telephone: 1-800-599-5188 or 647-365-5897

Via the internet at: www.kptissueinc.com

Presentation material referenced during the conference call will be available at www.kptissueinc.com.

A rebroadcast of the conference call will be available until midnight, November 19, 2021 by dialing 1-800-770-2030 or 647-362-9199 and entering passcode 9884406.

The replay of the webcast will remain available on the website until midnight, November 19, 2021.

About KP Tissue Inc. (KPT)KPT was created to acquire, and its business is limited to holding, a limited partnership interest in KPLP, which is accounted for as an investment on the equity basis. KPT currently holds a 14.5% interest in KPLP. For more information visit www.kptissueinc.com.

About Kruger Products L.P. (KPLP)KPLP is Canada's leading manufacturer of quality tissue products for household, industrial and commercial use. KPLP serves the Canadian consumer market with such well-known brands as Cashmere®, Purex®, SpongeTowels®, Scotties® and White Swan®. In the U.S., KPLP manufactures the White Cloud® brand, as well as many private label products. The Away-From-Home division manufactures and distributes high-quality, cost-effective product solutions to a wide range of commercial and public entities. KPLP has approximately 2,700 employees and operates nine FSC® COC-certified (FSC® C-104904) production facilities in North America. For more information visit www.krugerproducts.ca.

Non-IFRS MeasuresThis press release uses certain non-IFRS financial measures which KPLP believes provide useful information to management of KPLP and the readers of the financial information in measuring the financial performance and financial condition of KPLP. These measures do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similarly titled measures presented by other companies. An example of such a measure is Adjusted EBITDA. Beginning with Q4 2015 in accordance with Canadian Securities Administrators Staff Notice 52-306 (Revised), we have referenced Adjusted EBITDA as a non-IFRS financial measure. This term replaces the previously referenced non-IFRS financial measure EBITDA. Adjusted EBITDA is not a measurement of operating performance computed in accordance with IFRS and should not be considered as a substitute for operating income, net income or cash flows from operating activities computed in accordance with IFRS. “Adjusted EBITDA” is calculated by KPLP as net income (loss) before (i) interest expense, (ii) income taxes, (iii) depreciation, (iv) amortization, (v) impairment (gain on sale) of non-financial assets, (vi) loss (gain) on disposal of property, plant and equipment, (vii) foreign exchange loss (gain), (viii) costs related to restructuring activities, (ix) changes in amortized cost of Partnership units liability, (x) change in fair value of derivatives, (xi) consulting costs related to operational transformation initiatives, (xii) corporate development related costs and (xiii) loss (gain) on sale of shares. A reconciliation of Adjusted EBITDA to the relevant reported results can be found in the MD&A of KPT and KPLP for the quarter ended September 30, 2021, available on SEDAR at www.sedar.com.

COVID-19In March 2020, the World Health Organization characterized the outbreak of the novel strain of coronavirus, specifically identified as “COVID-19” as a global pandemic. There remains significant uncertainty as to the duration and impact of the COVID-19 outbreak at this time. It is not possible to reliably estimate or quantify the impact this pandemic may have on the financial results and condition of KPLP in future periods.

Forward-Looking StatementsCertain statements in this press release about KPT’s and KPLP's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements or any other future events or developments constitute forward-looking statements. Forward-looking statements in this press release include, but are not limited to, the anticipated benefits of the TAD Sherbrooke Project and the Sherbrooke Expansion Project and the expected dates for commencement of construction and production of the Sherbrooke Expansion Project. The words "may", "will", "would", "should", "could", "expects", "plans", "intends", "trends", "indications", "anticipates", "believes", "estimates", "predicts", "likely" or "potential" or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. The forward-looking statements are based on certain key expectations and assumptions made by KPT or KPLP. Although KPT and KPLP believe that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking statements since no assurance can be given that such expectations and assumptions will prove to be correct.

The outlook provided in respect of Adjusted EBITDA for Q4 2021 is forward-looking information and is subject to the risk and uncertainties referred to below. The purpose of the outlook is to provide the reader with an indication of management’s expectations, at the date of this press release, regarding KPLP’s future financial performance. Readers are cautioned that this information may not be appropriate for other purposes.

Many factors could cause KPLP’s actual results, level of activity, performance or achievements or future events or developments (which could in turn affect the economic benefits derived from KPT’s economic interest in KPLP) to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the following factors, which are discussed in greater detail in the “Risk Factors – Risks Related to KPLP’s Business” section of the KPT Annual Information Form dated March 11, 2021 available on SEDAR at www.sedar.com (the Annual Information Form), except for the risks associated with the Sherbrooke Expansion Project, which are discussed in greater detail in Risk Factors in the MD&A of KPT and KPLP for the 3-month and 9-month periods ended September 30, 2021 available on SEDAR at www.sedar.com: Kruger Inc.’s influence over KPLP; KPLP’s reliance on Kruger Inc.; consequences of an event of insolvency relating to Kruger Inc.; risks associated with the TAD Sherbrooke Project; operational risks; significant increases in input costs; reduction in supply of fibre; increased pricing pressure and intense competition; KPLP’s inability to innovate effectively; adverse economic conditions; dependence on key retail trade customers; damage to the reputation of KPLP or KPLP’s brands; KPLP’s sales being less than anticipated; KPLP’s failure to implement its business and operating strategies; KPLP’s obligation to make regular capital expenditures; KPLP’s entering into unsuccessful acquisitions; KPLP’s dependence on key personnel; KPLP’s inability to retain its existing customers or obtain new customers; KPLP’s loss of key suppliers; KPLP’s failure to adequately protect its intellectual property rights; KPLP’s reliance on third party intellectual property licenses; adverse litigation and other claims affecting KPLP; material expenditures due to comprehensive environmental regulation affecting KPLP’s cash flow; KPLP’s pension obligations are significant and can be materially higher than predicted if KPLP Management’s underlying assumptions are incorrect; labour disputes adversely affecting KPLP’s cost structure and KPLP’s ability to run its plants; exchange rate and U.S. competitors; KPLP’s inability to service all of its indebtedness; exposure to potential consumer product liability; covenant compliance; interest rate and refinancing risk; information technology; cyber-security; insurance; internal controls; trade related; and risk related to COVID-19.

Readers should not place undue reliance on forward-looking statements made herein. The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. The forward-looking information contained herein is made as of the date of press release and KPT undertakes no obligation to publicly update such forward-looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws.

INFORMATION:

Francois ParoyanGeneral Counsel and Corporate SecretaryKP Tissue Inc.Tel.: 905.812.6936francois.paroyan@krugerproducts.ca

INVESTORS:

Mike BaldesarraDirector of Investor RelationsKP Tissue Inc. Tel.: 905.812.6962IR@KPTissueinc.com

  Kruger Products L.P.
  Unaudited Condensed Consolidated Statements of Financial Position
  (thousands of Canadian dollars)
         
         
    September 30, 2021   December 31, 2020
    $   $
Assets      
Current assets      
  Cash, cash equivalents and restricted cash 118,639     128,739  
  Trade and other receivables 98,827     88,041  
  Receivables from related parties 1,076     13  
  Advances to partners 9,937     5,647  
  Inventories 258,189     215,934  
  Income tax recoverable 505     358  
  Prepaid expenses 8,243     8,315  
    495,416     447,047  
Non-current assets      
  Property, plant and equipment 1,207,540     1,194,191  
  Right-of-use assets 107,002     107,633  
  Other long-term assets 40,364     10  
  Goodwill 152,021     152,021  
  Intangible assets 30,084     26,205  
  Deferred income taxes 33,383     24,217  
Total assets 2,065,810     1,951,324  
         
Liabilities      
Current liabilities      
  Trade and other payables 231,904     332,072  
  Payables to related parties 7,429     9,097  
  Income tax payable 371     554  
  Distributions payable 12,202     11,919  
  Current portion of provisions 3,192     4,913  
  Current portion of long-term debt 39,205     9,495  
  Current portion of lease liabilities 30,175     25,341  
    324,478     393,391  
Non-current liabilities      
  Long-term debt 915,142     743,978  
  Long-term lease liabilities 99,799     105,634  
  Long-term payable to related party 41,777     -  
  Long-term provisions 8,885     9,549  
  Other long-term liabilities -     575  
  Pensions 26,972     161,333  
  Post-retirement benefits 57,747     63,038  
  Liabilities to non-unitholders 1,474,800     1,477,498  
  Current portion of Partnership units liability 14,132     31,244  
  Long-term portion of Partnership units liability 164,040     154,180  
  Total Partnership units liability 178,172     185,424  
Total liabilities 1,652,972     1,662,922  
         
Equity      
  Partnership units 455,939     439,571  
  Deficit (116,504 )   (224,503 )
  Accumulated other comprehensive income 73,403     73,334  
Total equity 412,838     288,402  
Total equity and liabilities 2,065,810     1,951,324  
         

Kruger Products L.P.
Unaudited Condensed Consolidated Statements of Comprehensive Income
(thousands of Canadian dollars)
               
               
  3-month   3-month   9-month   9-month
  period ended   period ended   period ended   period ended
  September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020
  $   $   $   $
               
               
               
Revenue 391,392     369,103     1,041,132     1,131,012  
               
Expenses              
     Cost of sales 345,577     307,733     903,885     932,255  
     Selling, general and administrative expenses 29,055     31,267     86,404     91,393  
     Loss on sale of non-financial assets 2     -     5     1  
     Restructuring costs, net 166     52     207     1,273  
               
Operating income 16,592     30,051     50,631     106,090  
               
     Interest expense 18,740     9,746     47,925     31,659  
     Other expense 11,728     2,477     10,781     10,629  
               
Income (loss) before income taxes (13,876 )   17,828     (8,075 )   63,802  
               
Income taxes (4,618 )   (627 )   (7,823 )   8,055  
               
Net income (loss) for the period (9,258 )   18,455     (252 )   55,747  
               
Other comprehensive income (loss)              
     Items that will not be reclassified to net income (loss):              
     Remeasurements of pensions 44,377     (4,142 )   138,418     (40,797 )
     Remeasurements of post-retirement benefits 1,670     (439 )   6,019     (3,827 )
     Items that may be subsequently reclassified to net income (loss):              
     Cumulative translation adjustment 7,441     (6,320 )   69     7,907  
               
Total other comprehensive income (loss) for the period 53,488     (10,901 )   144,506     (36,717 )
               
Comprehensive income for the period 44,230     7,554     144,254     19,030  
               

Kruger Products L.P.
Unaudited Condensed Consolidated Statements of Cash Flows
(thousands of Canadian dollars)
       
       
  9-month   9-month
  period ended   period ended
  September 30, 2021   September 30, 2020
  $   $
Cash flows from (used in) operating activities      
Net income (loss) for the period (252 )   55,747  
Items not affecting cash      
     Depreciation 61,292     48,497  
     Amortization 2,539     1,184  
     Loss on sale of property, plant and equipment 326     87  
     Change in amortized cost of Partnership units liability 10,283     10,903  
     Foreign exchange loss 498     86  
     Change in fair value of derivatives -     (360 )
     Interest expense 47,925     31,659  
     Pension and post-retirement benefits 12,486     11,121  
     Provisions 1,547     6,137  
     Income taxes (7,823 )   8,055  
     Loss on sale of non-financial assets 5     1  
     Total items not affecting cash 129,078     117,370  
       
Net change in non-cash working capital (120,743 )   27,086  
Contributions to pension and post-retirement benefit plans (11,451 )   (11,793 )
Provisions paid (4,173 )   (2,054 )
Income tax payments (2,019 )   (1,808 )
Net cash from (used in) operating activities (9,560 )   184,548  
       
Cash flows from (used in) investing activities      
Purchases of property, plant and equipment (19,438 )   (12,758 )
Purchases of property, plant and equipment related to the TAD Sherbrooke Project (88,273 )   (194,118 )
Interest paid on credit facilities related to the TAD Sherbrooke Project (608 )   (7,167 )
Purchases of software (774 )   (1,633 )
Proceeds on sale of shares -     992  
Proceeds on sale of property, plant and equipment 8     -  
Net cash used in investing activities (109,085 )   (214,684 )
       
Cash flows from (used in) financing activities      
Proceeds from long-term debt 225,197     193,538  
Repayment of long-term debt (21,913 )   (84,520 )
Payment of deferred financing fees (8,935 )   (500 )
Payment of lease liabilities (18,954 )   (14,506 )
Interest paid on long-term debt (24,753 )   (21,762 )
Distributions and advances paid, net (41,360 )   (18,372 )
Net cash from financing activities 109,282     53,878  
       
Effect of exchange rate changes on cash and cash      
     equivalents held in foreign currency (737 )   586  
       
Increase (decrease) in cash, cash equivalents and restricted cash during the period (10,100 )   24,328  
       
Cash, cash equivalents and restricted cash - Beginning of period 128,739     93,141  
       
Cash, cash equivalents and restricted cash - End of period 118,639     117,469  
       

Kruger Products L.P.
Segment and Geographic Results
(thousands of Canadian dollars)
                 
    3-month   3-month   9-month   9-month
    period ended   period ended   period ended   period ended
    September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020
    $   $   $   $
                 
Segment Information                
                 
Segment Revenue                
Consumer   332,416     319,869     896,144     971,400  
AFH   58,976     49,234     144,988     159,612  
                 
Total segment revenue   391,392     369,103     1,041,132     1,131,012  
                 
Adjusted EBITDA                
Consumer   39,092     55,264     123,563     179,193  
AFH   2,162     (3,466 )   (3,174 )   (6,632 )
Corporate and other costs   (941 )   (5,550 )   (5,296 )   (10,939 )
                 
Total Adjusted EBITDA   40,313     46,248     115,093     161,622  
                 
Reconciliation to Net income (loss)                
                 
Depreciation and amortization   23,464     15,948     63,831     49,681  
Interest expense   18,740     9,746     47,925     31,659  
Change in amortized cost of Partnership units liability   3,427     5,863     10,283     10,903  
Change in fair value of derivatives   -     -     -     (360 )
Loss on sale of property, plant and equipment   62     38     326     87  
Loss on sale of non-financial assets   2     -     5     1  
Restructuring costs, net   166     52     207     1,273  
Foreign exchange (gain) loss   8,301     (3,386 )   498     86  
Corporate development related costs   27     159     93     159  
Consulting costs related to operational transformation initiatives   -     -     -     4,331  
                 
Income (loss) before income taxes   (13,876 )   17,828     (8,075 )   63,802  
                 
Income taxes   (4,618 )   (627 )   (7,823 )   8,055  
                 
Net income (loss)   (9,258 )   18,455     (252 )   55,747  
                 
Geographic Revenue                
                 
Canada   233,529     223,272     647,516     671,805  
US   157,863     145,831     393,616     459,207  
                 
Total revenue   391,392     369,103     1,041,132     1,131,012  
                 

KP Tissue Inc.
Unaudited Condensed Statements of Financial Position
(thousands of Canadian dollars)
       
       
  September 30, 2021   December 31, 2020
  $   $
Assets      
       
Current assets      
Distributions receivable 1,774     1,755  
Receivable from Partnership -     21  
Income tax recoverable 106     -  
  1,880     1,776  
       
Non-current assets      
Investment in associate 80,017     69,537  
       
Total Assets 81,897     71,313  
       
Liabilities      
       
Current liabilities      
Dividend payable 1,774     1,755  
Payable to Partnership 74     -  
Current portion of advances from Partnership 1,478     874  
Income tax payable -     1,722  
  3,326     4,351  
Non-current liabilities      
Deferred income taxes 1,022     634  
       
Total liabilities 4,348     4,985  
       
Equity      
       
Common shares 21,471     20,355  
Contributed surplus 144,819     144,819  
Deficit (101,760 )   (111,907 )
Accumulated other comprehensive income 13,019     13,061  
       
Total equity 77,549     66,328  
       
Total liabilities and equity 81,897     71,313  
       

KP Tissue Inc.
Unaudited Condensed Statements of Comprehensive Income (Loss)
(thousands of Canadian dollars, except share and per share amounts)
               
               
  3-month period ended September 30, 2021   3-month period ended September 30, 2020   9-month period ended September 30, 2021   9-month period ended September 30, 2020
  $   $   $   $
               
               
Equity income (loss) (2,686 )   1,355     (4,033 )   4,155  
Dilution gain 81     77     243     528  
               
Income (loss) before income taxes (2,605 )   1,432     (3,790 )   4,683  
               
Income taxes (382 )   667     (1,542 )   2,340  
               
Net income (loss) for the period (2,223 )   765     (2,248 )   2,343  
               
Other comprehensive income (loss)              
net of tax expense (recovery)              
   Items that will not be reclassified to net income (loss):              
   Remeasurements of pensions 5,600     (355 )   17,152     (4,010 )
   Remeasurements of post-retirement benefits 147     (39 )   536     (348 )
   Items that may be subsequently reclassified to net income (loss):              
   Cumulative translation adjustment 1,092     (1,003 )   (42 )   1,128  
               
Total other comprehensive income (loss) for the period 6,839     (1,397 )   17,646     (3,230 )
               
Comprehensive income (loss) for the period 4,616     (632 )   15,398     (887 )
               
Basic earnings (loss) per share (0.23 )   0.08     (0.23 )   0.24  
               
Weighted average number of shares outstanding 9,853,722     9,721,047     9,817,280     9,688,788  
               

KP Tissue Inc.
Unaudited Condensed Statement of Cash Flows
(thousands of Canadian dollars)
       
       
  9-month period ended September 30, 2021   9-month period ended September 30, 2020
  $   $
Cash flows from (used in) operating activities      
Net income (loss) for the period (2,248 )   2,343  
Items not affecting cash      
Equity (income) loss 4,033     (4,155 )
Dilution gain (243 )   (528 )
Income taxes (1,542 )   2,340  
Total items not affecting cash 2,248     (2,343 )
       
Net change in non-cash working capital 95     94  
Tax payments (3,311 )   (1,504 )
Tax Distribution received 1,738     781  
Advances received 1,478     629  
       
Net cash from (used in) operating activities -     -  
       
Cash flows from investing activities      
Partnership unit distributions received 4,158     4,193  
       
Net cash from investing activities 4,158     4,193  
       
Cash flows used in financing activities      
Dividends paid (4,158 )   (4,193 )
       
Net cash used in financing activities (4,158 )   (4,193 )
       
Increase (decrease) in cash and cash equivalents during the period -     -  
       
Cash and cash equivalents - Beginning of period -     -  
       
Cash and cash equivalents - End of period -     -  
KP Tissue (TSX:KPT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos KP Tissue.
KP Tissue (TSX:KPT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos KP Tissue.